Medications for Intraductal Noninfiltrating Carcinoma

5 results

  • Tamoxifen citrate (tamoxifen citrate)

    (Tamoxifen Citrate)
    Dr. Reddy's Laboratories Inc.
    Usage: Tamoxifen citrate tablets are indicated for the treatment of metastatic breast cancer, node-positive and node-negative adjuvant breast cancer, ductal carcinoma in situ (DCIS), and to reduce breast cancer incidence in high-risk women. It is particularly effective for estrogen receptor-positive tumors and requires individual risk assessment for therapy.

  • Tamoxifen citrate (tamoxifen citrate)

    (Tamoxifen Citrate)
    Proficient Rx LP
    Usage: Tamoxifen citrate tablets are indicated for treating metastatic breast cancer, as adjuvant therapy post-surgery in node-positive and node-negative cases, for reducing invasive breast cancer risk in women with ductal carcinoma in situ, and for decreasing breast cancer incidence in high-risk women.

  • Tamoxifen citrate (tamoxifen citrate)

    (Tamoxifen Citrate)
    Aurobindo Pharma Limited
    Usage: Tamoxifen citrate tablets are indicated for treating metastatic breast cancer in both women and men, serving as an adjuvant therapy post-mastectomy, and for reducing invasive breast cancer risk in women with DCIS. Additionally, it is prescribed to high-risk women to lower breast cancer incidence based on specific risk criteria.

  • Tamoxifen citrate (tamoxifen citrate)

    (Tamoxifen Citrate)
    NuCare Pharmaceuticals,Inc.
    Usage: Tamoxifen citrate is indicated for treating metastatic breast cancer, adjuvant therapy after surgery, and ductal carcinoma in situ (DCIS). It also reduces breast cancer incidence in high-risk women. Efficacy is greater in estrogen receptor-positive tumors, and individual risk assessments are crucial when considering therapy.

  • Tamoxifen citrate (tamoxifen citrate)

    (Tamoxifen Citrate)
    Bryant Ranch Prepack
    Usage: Tamoxifen citrate tablets are indicated for treating metastatic and node-positive breast cancer in men and women, reducing contralateral breast cancer risk, and adjunctive therapy post-surgery. They also reduce invasive breast cancer risk in women with ductal carcinoma in situ and are indicated for preventing breast cancer in high-risk women.